Malignant Neoplasm — Drugs

Loading cancer entity…

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Asparaginase	EU EMA	Acute Lymphoblastic Leukemia	Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.	approved	Jan 14, 2016	ema
Atezolizumab	US FDA	Lung Small Cell Carcinoma	in combination with lurbinectedin, for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Lung Non-Small Cell Carcinoma	for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Hepatocellular Carcinoma	Hepatocellular Carcinoma (HCC) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Lung Small Cell Carcinoma	Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Melanoma	Melanoma in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Lung Non-Small Cell Carcinoma	for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Malignant Bladder Neoplasm	Muscle Invasive Bladder Cancer (MIBC) as adjuvant treatment of adult patients with MIBC after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Lung Non-Small Cell Carcinoma	Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.	approved	May 18, 2016	openfda
Atezolizumab	US FDA	Alveolar Soft Part Sarcoma	Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS.	approved	May 18, 2016	openfda
Aumolertinib	EU EMA	Lung Non-Small Cell Carcinoma	Aumseqa as monotherapy is indicated for:- the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC)whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (forbiomarker-based patient selection, see section 4.2).- the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC (forbiomarker-based patient selection, see section 4.2)	approved	Feb 12, 2026	ema
Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor	EU EMA	Malignant Prostate Neoplasm	Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.	withdrawnsince May 6, 2015	Sep 6, 2013	ema
Avelumab	US FDA	Renal Cell Carcinoma	Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC.	approved	Mar 23, 2017	openfda
Avelumab	US FDA	Merkel Cell Carcinoma	Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC.	approved	Mar 23, 2017	openfda
Avelumab	US FDA	Urothelial Carcinoma	Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.	approved	Mar 23, 2017	openfda
Axitinib	EU EMA	Renal Cell Carcinoma	Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.	approved	Sep 19, 2024	ema
Axitinib	EU EMA	Renal Cell Carcinoma	Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.	approved	Sep 3, 2012	ema
Axitinib	US FDA	Renal Cell Carcinoma	as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.	approved	Jan 27, 2012	openfda
Axitinib	US FDA	Renal Cell Carcinoma	in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).	approved	Jan 27, 2012	openfda
Azacitidine	EU EMA	Acute Myeloid Leukemia	Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT).	approved	Jun 17, 2021	ema
Azacitidine	US FDA	Acute Myeloid Leukemia	ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ).	approved	Sep 1, 2020	openfda
Azacitidine	US FDA	Juvenile Myelomonocytic Leukemia	Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).	approved	May 19, 2004	openfda
Belantamab Mafodotin	EU EMA	Multiple Myeloma	Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma: in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.	approved	Jul 23, 2025	ema
Belantamab Mafodotin	EU EMA	Multiple Myeloma	Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.conditional	withdrawnsince Feb 23, 2024	Aug 25, 2020	ema
Belantamab Mafodotin	US FDA	Multiple Myeloma	BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. BLENREP, a B‑cell maturation antigen (BCMA)‑directed antibody and microtubule inhibitor conjugate, is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. ( 1 )	approved	Oct 23, 2025	openfda
Belinostat	US FDA	Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see Clinical Studies ( 14 )]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.( 1 )accelerated	approved	Jul 3, 2014	openfda
Belzutifan	US FDA	Clear Cell Renal Cell Carcinoma	Renal Cell Carcinoma with a Clear Cell Component (ccRCC) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the adjuvant treatment of adult patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.	approved	Aug 13, 2021	openfda
Belzutifan	US FDA	Clear Cell Renal Cell Carcinoma	as monotherapy, for treatment of adult patients with advanced ccRCC following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).	approved	Aug 13, 2021	openfda
Bendamustine	US FDA	Chronic Lymphocytic Leukemia	Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	approved	Jul 3, 2025	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	approved	Jul 3, 2025	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	approved	Dec 15, 2022	openfda
Bendamustine	US FDA	Chronic Lymphocytic Leukemia	Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	approved	Dec 15, 2022	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	approved	Dec 7, 2022	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 )	approved	Dec 7, 2022	openfda
Bendamustine	US FDA	Chronic Lymphocytic Leukemia	Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	approved	Dec 7, 2022	openfda
Bendamustine	US FDA	Chronic Lymphocytic Leukemia	Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	approved	May 15, 2018	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	approved	May 15, 2018	openfda
Bendamustine	US FDA	Chronic Lymphocytic Leukemia	Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	approved	Dec 7, 2015	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	approved	Dec 7, 2015	openfda
Bendamustine	US FDA	Chronic Lymphocytic Leukemia	Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	approved	Mar 20, 2008	openfda
Bendamustine	US FDA	Indolent B-Cell Non-Hodgkin Lymphoma	Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	approved	Mar 20, 2008	openfda
Bevacizumab	US FDA	Malignant Cervical Neoplasm	Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.	approved	Feb 26, 2004	openfda
Bevacizumab	US FDA	Hepatocellular Carcinoma	Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy	approved	Feb 26, 2004	openfda
Bevacizumab	US FDA	Renal Cell Carcinoma	Metastatic renal cell carcinoma in combination with interferon alfa.	approved	Feb 26, 2004	openfda
Bevacizumab	US FDA	Glioblastoma	Recurrent glioblastoma in adults.	approved	Feb 26, 2004	openfda
Bevacizumab	US FDA	Lung Non-Squamous Non-Small Cell Carcinoma	Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.	approved	Feb 26, 2004	openfda
Bevacizumab	US FDA	Malignant Colon Neoplasm	Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer.	approved	Feb 26, 2004	openfda
Bevacizumab	US FDA	Malignant Peritoneal Neoplasm	Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection	approved	Feb 26, 2004	openfda

Drug

Jurisdiction · authority

Cancer

Indication

Status

Approval date

Source

Asparaginase

EU EMA

Acute Lymphoblastic Leukemia

Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.

approved

Jan 14, 2016

ema

Atezolizumab

US FDA

Lung Small Cell Carcinoma

in combination with lurbinectedin, for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.

approved

May 18, 2016

Therapy	Evidence items (count)	Sensitivity / response	Resistance
Cetuximab	401	91	309
Dasatinib	306	173	133
Erlotinib	260	166	94
Crizotinib	255	135	120
Vemurafenib	238	129	109
Gefitinib	183	140	43
Imatinib	165	73	92
Trametinib	137	111	26
Afatinib	129	120	9
Panitumumab	127	34	93
Trastuzumab	127	90	37
Olaparib	105	102	3
Dabrafenib	99

Approvals by jurisdiction

Therapies appearing in curated evidence